Hologic (HOLX) announced that it has entered into an agreement with the Centers for Disease Control and Prevention, or CDC, to develop analyte specific reagents, or ASRs, the “active ingredients” of laboratory-developed tests used to identify specific diseases or conditions that would aid in the detection of H5N1 bird flu. The contract will fund proof-of-concept development of ASRs primers and probes, in this case that could eventually be incorporated into laboratory-developed tests designed to detect H5N1. While Hologic does not currently intend to make these ASRs commercially available, the company may explore future commercialization should the need for rapid implementation of H5N1 testing arise.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic price target lowered to $84 from $90 at UBS
- Salesforce upgraded, ServiceNow downgraded: Wall Street’s top analyst calls
- Hologic initiated with a Peer Perform at Wolfe amid near-term headwinds
- Hologic initiated with a Peer Perform at Wolfe Research
- Cervical cancer recommendations lift ‘minor overhang’ on Hologic, says Leerink